Neil A. Petry, M.S., RPh, BCNP, FAPhA

  • Associate Professor of Radiology
  • Faculty, Medical Physics Program
Department/Division
  • Research
Address DUMC Box 3304
Durham, NC 27710
Telephone 919-684-5636
Training
  • MS, Nuclear Pharmacy, Purdue University, 1977
  • BS, Pharmacy, Purdue University, 1975
Research Interests As Director of the Duke Medical Center Radiopharmacy, which is permitted by the North Carolina Board of Pharmacy, I am responsible for the procurement, formulation, quality control testing, and dispensing of all radiopharmaceuticals for diagnostic, therapeutic, and research purposes for use in patients in Duke Hospital. Service accomplishments in fiscal year 2008-2009 included providing all radiopharmaceuticals used for routine patient care at Duke Medical Center. In addition, the Radiopharmacy service participated in a wide variety of clinical research protocols undertaken by Duke investigators either by consultation regarding pharmaceutical formulation of research compounds or actually performing these formulations as a specialized service. The major accomplishment over the last year was to move the Radiopharmacy operation into a new state of the art USP <797> compliant clean room environment. This new lab space is specifically designed to satisfy a wide variety of sterile radiopharmaceutical compounding needs for both routine patient care and clinical research well into the future. My general research interests focus on the development and clinical evaluation of diagnostic and therapeutic radiopharmaceuticals for patient care. Specific research interests focus on the clinical applications of 1.) Carbon C-11, Nitrogen N-13, Oxygen 0-15 and Fluorine F-18 labeled radiopharmaceuticals for Positron Emission Tomography (PET) based molecular imaging and 2.) Radiolabeling antibodies, small molecules and peptides with Gallium Ga-68 for diagnosis and therapeutic radionuclides for treatment of human cancers. Finally, I am interested in the development of pharmaceutical care models in nuclear medicine to optimize the patient's health related quality of life, and achieve positive clinical outcomes, within realistic economic expenditures.
  • Sampson JH, Brady M, Raghavan R, Mehta AI, Friedman AH, Reardon DA, Petry NA, Barboriak DP, Wong TZ, Zalutsky MR, Lally-Goss D, Bigner DD. Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery. 2011 Sep;69(3):668-76. Abstract
  • Norenberg JP, Petry NA, Schwarz S. Operation of a radiopharmacy for a clinical trial. Semin Nucl Med. 2010 Sep;40(5):347-56. Abstract
  • Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE 2nd, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008 Jun;10(3):320-9. Abstract
  • Wong TZ, Lacy JL, Petry NA, Hawk TC, Sporn TA, Dewhirst MW, Vlahovic G. PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. AJR Am J Roentgenol. 2008 Feb;190(2):427-32. Abstract
  • Chin BB, Metzler SD, Lemaire A, Curcio A, Vemulapalli S, Greer KL, Petry NA, Turkington TG, Coleman RE, Rockman H, Jaszczak RJ. Left ventricular functional assessment in mice: feasibility of high spatial and temporal resolution ECG-gated blood pool SPECT. Radiology. 2007 Nov;245(2):440-8. Abstract
  • Sampson JH, Brady ML, Petry NA, Croteau D, Friedman AH, Friedman HS, Wong T, Bigner DD, Pastan I, Puri RK, Pedain C. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery. 2007 Feb;60(2 Suppl 1):ONS89-98; discussion ONS98-9. Abstract
  • Vemulapalli S, Metzler SD, Akabani G, Petry NA, Niehaus NJ, Liu X, Patil NH, Greer KL, Jaszczak RJ, Coleman RE, Dong C, Goldschmidt-Clermont PJ, Chin BB. Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT. Radiology. 2007 Jan;242(1):198-207. Abstract
  • Kleiter MM, Yu D, Mohammadian LA, Niehaus N, Spasojevic I, Sanders L, Viglianti BL, Yarmolenko PS, Hauck M, Petry NA, Wong TZ, Dewhirst MW, Thrall DE. A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation. Clin Cancer Res. 2006 Nov 15;12(22):6800-7. Abstract
  • Hung JC, Augustine SC, Cheng KT, Green RL, Hopkins WM, Laven DL, Nelson BR, Petry NA, Ponto JA, Quinton TM, Swanson DP. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines. J Am Pharm Assoc (Wash). 2002 Sep-Oct;42(5):789-98. Abstract
  • Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, Armor T, Stubbs JB, Maresca KP, Stabin MG, Joyal JL, Eckelman WC, Babich JW. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013 Mar;54(3):380-7. Abstract
  • Cooper JF, Petry NA, Engelbrecht H, Breslow K. Alumina Depyrogenates F 18 Fludeoxyglucose Injection during Purification Processes. PDA J Pharm Sci Technol. 2012 May-Jun;66(3):214-20. Abstract